Ieq Capital LLC Has $8.50 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

Ieq Capital LLC increased its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 14.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 320,472 shares of the biopharmaceutical company's stock after purchasing an additional 40,117 shares during the period. Ieq Capital LLC's holdings in Pfizer were worth $8,502,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Wells Trecaso Financial Group LLC boosted its holdings in Pfizer by 2.5% in the third quarter. Wells Trecaso Financial Group LLC now owns 14,361 shares of the biopharmaceutical company's stock valued at $416,000 after acquiring an additional 350 shares during the last quarter. Washington Trust Advisors Inc. raised its holdings in Pfizer by 0.7% during the 3rd quarter. Washington Trust Advisors Inc. now owns 49,216 shares of the biopharmaceutical company's stock worth $1,424,000 after purchasing an additional 360 shares during the last quarter. PSI Advisors LLC lifted its position in Pfizer by 1.4% during the 4th quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company's stock valued at $738,000 after purchasing an additional 385 shares during the period. Western Pacific Wealth Management LP boosted its stake in shares of Pfizer by 10.5% in the 3rd quarter. Western Pacific Wealth Management LP now owns 4,073 shares of the biopharmaceutical company's stock valued at $118,000 after purchasing an additional 386 shares during the last quarter. Finally, Waddell & Associates LLC grew its position in shares of Pfizer by 1.6% during the 3rd quarter. Waddell & Associates LLC now owns 24,978 shares of the biopharmaceutical company's stock worth $723,000 after buying an additional 388 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Up 1.6 %

PFE stock traded up $0.42 during mid-day trading on Friday, hitting $26.32. 54,560,140 shares of the company were exchanged, compared to its average volume of 38,524,395. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The firm's 50 day simple moving average is $26.28 and its 200 day simple moving average is $27.44. The firm has a market cap of $149.14 billion, a P/E ratio of 18.66, a P/E/G ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. The business had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm's quarterly revenue was up 24.7% on a year-over-year basis. During the same period last year, the business posted $0.10 earnings per share. On average, sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.54%. This is a positive change from Pfizer's previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. Pfizer's payout ratio is 121.99%.

Insider Buying and Selling

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of Pfizer stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares of the company's stock, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.06% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

PFE has been the topic of several analyst reports. Wolfe Research assumed coverage on shares of Pfizer in a research note on Friday, November 15th. They issued an "underperform" rating and a $25.00 price objective on the stock. Evercore ISI raised Pfizer to a "strong-buy" rating in a research note on Wednesday, October 30th. Guggenheim reaffirmed a "buy" rating and set a $33.00 price objective on shares of Pfizer in a research note on Monday, February 10th. StockNews.com lowered Pfizer from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, November 20th. Finally, UBS Group decreased their target price on Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a research report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Pfizer has a consensus rating of "Moderate Buy" and an average target price of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.